GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (XTER:MRK) » Definitions » Ending Cash Position

Merck KGaA (XTER:MRK) Ending Cash Position : €1,982 Mil (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Merck KGaA Ending Cash Position?

Merck KGaA's Ending Cash Position for the quarter that ended in Dec. 2023 was €1,982 Mil.

Merck KGaA's quarterly Ending Cash Position increased from Jun. 2023 (€1,761 Mil) to Sep. 2023 (€2,365 Mil) but then declined from Sep. 2023 (€2,365 Mil) to Dec. 2023 (€1,982 Mil).

Merck KGaA's annual Ending Cash Position declined from Dec. 2021 (€1,899 Mil) to Dec. 2022 (€1,854 Mil) but then increased from Dec. 2022 (€1,854 Mil) to Dec. 2023 (€1,982 Mil).


Merck KGaA Ending Cash Position Historical Data

The historical data trend for Merck KGaA's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck KGaA Ending Cash Position Chart

Merck KGaA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 781.00 1,355.00 1,899.00 1,854.00 1,982.00

Merck KGaA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,854.00 1,584.00 1,761.00 2,365.00 1,982.00

Merck KGaA Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Merck KGaA's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1853+129
=1,982

Merck KGaA's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2366+-384
=1,982


Merck KGaA Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Merck KGaA's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck KGaA (XTER:MRK) Business Description

Address
Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Executives
Belén Garijo Lopez Chair of the Executive Board
Peter Guenter Member of the Executive Board
Dr. Matthias Heinzel Member of the Executive Board
Dr. Marcus Kuhnert Board of Directors

Merck KGaA (XTER:MRK) Headlines

From GuruFocus

Merck & Co Inc at ASCO Annual Meeting Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024